| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2b topline data readout example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Respiratory System | ||
Phase 2b topline data readout example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Respiratory System | ||
Phase 2b topline data readout example | Phase 2b | — | Subscribe to access the data. | Small Molecules | Respiratory System |
Recent Updates
Recently added Catalysts
Avalyn Pharma Inc.
$38.86
+0.61 (+1.59%)
D 33Pipeline Score Richly Valued Pharma · Clinical
Market Cap
1.72 B
EPS
-
P/E Ratio
-
Value Trade
4.93 M
9.59 %
Week
35.73 %
1 Month
38.24 %
3 Month
31.77 %
6 Month
10.92 %
5 Year
10.92 %
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
194.79 K
52 Week Range
25.05 - 32.23
% held by Insiders
42.56 %
% held by Institutions
65.14 %
Enterprise Value
1.32 B
Total Shares
44.32 M
Short %
7.93 %
Float Shares
27.52 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Avalyn Pharma Inc.
4Total events
2Upcoming
2Tier-1 (high impact)
2026 – 2027Coverage
Upcoming catalysts 2
TBD
T1Topline Readout
Subscribe to view catalyst details
TBD
T1Topline Readout
Subscribe to view catalyst details
Event history 2
TBD
▲Enrollment CompleteAP01Trial
Subscribe to view catalyst details
TBD
▲AbstractAP01Presentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2026-06-06 | AP01 (inhaled pirfenidone) | Phase 1b data readout | Phase 1b | — | – | – | – |
2026-06-06 | AP01 (inhaled pirfenidone) | Phase 1b data readout | Phase 1b | — | – | – | – |
2026-06-06 | AP01 (inhaled pirfenidone) | Phase 1b data readout | Phase 1b | — | – | – | – |
Drug Pipeline Intelligence
D33
Pipeline Score $73M
Pipeline ValueRichly Valued
Valuation Signal2
Drugs Scored0.0x
rNPV / MCap Top 45%
Micro Cap (rank 513 of 931)
Percentile RankAvalyn Pharma Inc. faces pipeline headwinds (33/100), with $182M risk-adjusted pipeline value, led by AP01 in Pulmonary Fibrosis (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AP01 Small molecule | Pulmonary Fibrosis | Phase 2 | NCT06329401 | 17% | $166M | ACTIVE NOT_RECRUITING | 375 | VERY_FAST | B (76) | Jun 1, 2027 | - | LOW Jul 2, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
AP01 | progressive pulmonary fibrosis | Phase 2b | 2026-05-06 | encouraging safety and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone Read More | Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference Read More | |
AP01 | progressive pulmonary fibrosis | Phase 2b | 2026-05-06 | encouraging safety and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone Read More | Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference Read More | |
AP01 | progressive pulmonary fibrosis | Phase 2b | 2026-05-06 | encouraging safety and clinical activity across Phase 1b and an ongoing, multi-year open-label extension trial, with long-term data supporting the potential to preserve lung function while improving tolerability relative to historical oral pirfenidone Read More | Avalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in AVLN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
AVLN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
AVLN▲ +5.4%on this news
Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Avalyn has completed enrollment for its MIST global Phase 2b trial of AP01, involving 398 patients. The company anticipates topline data to be available in the second half of 2027. Additionally, two abstracts have been accepted for presentation at the upcoming European Respiratory Society Congress, showcasing data on AP01 lung tissue distribution.
Read more →AVLNAvalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis Company expects to report topline 12-month clinical results in the second half of 2
Avalyn Pharma has successfully completed target enrollment of 375 patients for the Phase 2b MIST trial evaluating AP01, an inhaled formulation of pirfenidone for progressive pulmonary fibrosis (PPF). The trial aims to assess the safety and efficacy of AP01 compared to a placebo over 52 weeks. Topline results are anticipated in the second half of 2027, and the company expresses optimism about the potential benefits of AP01 based on previous clinical data.
Read more →AVLNAvalyn Reports First Quarter 2026 Financial Results and Recent Business Highlights
Avalyn Pharma reported its Q1 2026 financial results, highlighting progress in its clinical trials for inhaled therapies targeting pulmonary fibrosis. The company is on track to complete enrollment in the MIST Phase 2b trial of AP01 by mid-2026 and has initiated the AURA Phase 2 trial for AP02. Following a successful IPO, Avalyn has sufficient funds to support its operations through 2029. The company aims to redefine treatment standards for serious respiratory diseases.
Read more →AVLNAvalyn to Participate in the Jefferies Global Healthcare Conference
Avalyn Pharma Inc. will present a company overview at the Jefferies Global Healthcare Conference on June 4, 2026. The presentation will highlight Avalyn's innovative inhaled therapies aimed at treating serious respiratory diseases, particularly their ongoing clinical trials for pulmonary fibrosis. The company is focused on transforming treatment paradigms with optimized formulations of established antifibrotic medicines.
Read more →AVLNAvalyn Announces Additional Long-term Data on AP01, Inhaled Pirfenidone, for the Treatment of Pulmonary Fibrosis to be Presented at the European Alliance of Associations for Rheumatology 2026
Avalyn Pharma Inc. announced that it will present updated long-term data on AP01, an inhaled formulation of pirfenidone, at the EULAR 2026 conference. The findings from the ATLAS trial will focus on the drug's tolerability in patients with progressive pulmonary fibrosis over four years. This presentation aims to highlight the potential benefits of inhaled therapies for serious respiratory diseases.
Read more →AVLNAvalyn to Present Patient-Centered Research on AP01 Delivery and Supportive Care Experiences at American Thoracic Society 2026 International Conference
Avalyn Pharma will present patient-centered research at the ATS 2026 International Conference, focusing on inhaled therapies for pulmonary fibrosis. The presentations include findings from a usability study of the eFlow® Nebulizer System and patient perspectives on supportive healthcare experiences. Avalyn aims to enhance treatment through direct patient input and innovative inhaled formulations.
Read more →AVLNAvalyn Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Avalyn Pharma Inc. has successfully closed its initial public offering, raising $345 million through the sale of 19,166,667 shares at $18.00 each. The offering included the full exercise of an overallotment option by underwriters. The company's stock is now listed on the Nasdaq Global Select Market under the ticker AVLN.
Read more →Competitive Position
How AVLN ranks across every disease it competes inCompetitive Position is a premium feature
See how AVLN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial